Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Gannex Announces the First Cohort Dosed in a U.S. Clinical Study with THR-β Agonist ASC41

prnasiaApril 15, 2021

Tag: Gannex , Ascletis , ASC41

PharmaSources Customer Service